2012

Hier vindt u een chronologisch overzicht van wetenschappelijke publicaties in 2012, gepubliceerd door de klinische onderzoeksgroepen die betrokken zijn bij ATHENA/SHM.

 

Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.
Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; on behalf of the Beijing PRIMO cohort study and the CASCADE Collaboration in EuroCoord.
J Acquir Immune Defic Syndr. 2012 Dec 6. [Epub ahead of print] Abstract

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).
Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12. Abstract

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
D Grint, L Peters, M Vogel, M Beniowski, C Pradier, M Battegay, D Jevtovic, V Soriano, J Lundgren, J Rockstroh, O Kirk, A Mocroft
J Int AIDS Soc. 2012 Nov 11;15(6):18118. doi: 10.7448/IAS.15.6.18118. Abstract

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.
J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426. Abstract

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD.
Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26. Abstract

Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study.
Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord.
BMC Infect Dis. 2012 Sep 25;12:229. doi: 10.1186/1471-2334-12-229. Abstract

Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection.
Grijsen ML, Holman R, Wit FW, Gras L, Lowe SH, Brinkman K, de Wolf F, Prins JM.
AIDS. 2012 Sep 24;26(15):1974-7. Abstract

Could better tolerated HIV drug regimens improve patient outcome?
Smit M, Smit C, Cremin I, Garnett GP, Hallett T, de Wolf F.
AIDS. 2012 Sep 24;26(15):1953-9. Abstract

Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord.
AIDS. 2012 Sep 24;26(15):1917-26. Abstract

Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study.
van Sighem A, Vidondo B, Glass TR, Bucher HC, Vernazza P, Gebhardt M, de Wolf F, Derendinger S, Jeannin A, Bezemer D, Fraser C, Low N; Swiss HIV Cohort Study.
PLoS One. 2012;7(9):e44819. Epub 2012 Sep 14. Abstract

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.
Arch Intern Med. 2012 Sep 10;172(16):1252-5. doi: 10.1001/archinternmed.2012.2719 Abstract

Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data.
van Sighem A, Jansen I, Bezemer D, De Wolf F, Prins M, Stolte I, Fraser C.
AIDS. 2012 Sep 10;26(14):1840-3. doi: 10.1097/QAD.0b013e3283574df9. Abstract

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
HIV-CAUSAL Collaboration.
AIDS. 2012 Aug 24;26(13):1691-705. Abstract

No advantage of quadruple- or triple-class antiretroviral therapy as initial treatment in patients with very high viraemia.
Grijsen ML, Holman R, Gras L, Wit FW, Hoepelman AI, van den Berk GE, de Wolf F, Prins JM; ATHENA National Observational Cohort Study.
Antivir Ther. 2012;17(8):1609-13. doi: 10.3851/IMP2321. Epub 2012 Aug 22. Abstract

Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.
Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.
Antivir Ther. 2012;17(6):1039-48. doi: 10.3851/IMP2312. Epub 2012 Aug 15. Abstract

Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration.
HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
Antivir Ther. 2012;17(8):1541-50. doi: 10.3851/IMP2263. Epub 2012 Jul 24. Abstract

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.
Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord.
PLoS One. 2012;7(7):e41673. doi: 10.1371/journal.pone.0041673. Epub 2012 Jul 23. Abstract

Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
Zhang S, van Sighem A, Kesselring A, Gras L, Smit C, Prins JM, Kauffmann R, Richter C, de Wolf F, Reiss P.
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):265-72. doi: 10.1097/QAI.0b013e318258c651. Abstract

The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence?
Fung IC, Gambhir M, van Sighem A, de Wolf F, Garnett GP.
J Acquir Immune Defic Syndr. 2012 May 1;60(1):5-11. doi: 10.1097/QAI.0b013e3182487a20. Abstract

Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study.
Grijsen M, Koster G, van Vonderen M, van Kasteren M, Kootstra G, Steingrover R, de Wolf F, Prins J, Nieuwkerk P; Primo-SHM study group.
HIV Med. 2012 Nov;13(10):630-5. doi: 10.1111/j.1468-1293.2012.01020.x. Epub 2012 Apr 25. Abstract

All-cause mortality in treated HIV-infected adults with CD4 ?500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G.
Int J Epidemiol. 2012 Apr;41(2):433-45. doi: 10.1093/ije/dyr164. Epub 2011 Nov 28. Abstract

HCV coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ, Smit C, Godfried MH, Nellen JF, de Wolf F, Boer K, van der Ende ME.
J Infect. 2012 Apr;64(4):409-16. doi: 10.1016/j.jinf.2011.12.012. Epub 2011 Dec 23. Abstract

Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene & Kholoud Porter.
Clin. Invest. (2012) 2(3), 255–264 Artikel

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
HIV-CAUSAL Collaboration.
Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Abstract

No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial
Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.
PLoS Med. 2012;9(3):e1001196. Epub 2012 Mar 27. Abstract

CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE
The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
PLoS Med. 2012 March; 9(3): e1001194. Published online 2012 March 20. doi: 10.1371/journal.pmed.1001194 Artikel

Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa
Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.
PLoS ONE 7(3): e32369. doi:10.1371/journal.pone.0032369 Abstract

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A.
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b. Abstract

Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
van Lelyveld SF, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AM, Hoepelman AI; ATHENA national observational cohort study.
AIDS. 2012 Feb 20;26(4):465-74. doi: 10.1097/QAD.0b013e32834f32f8. Abstract

Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke.
Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD; D:A:D Study Group.
J Infect Dis. 2012 Feb 15;205(4):535-9. doi: 10.1093/infdis/jir788. Epub 2012 Jan 5. Abstract

The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).
HIV Med. 2012 Feb;13(2):89-97. doi: 10.1111/j.1468-1293.2011.00940.x. Epub 2011 Aug 7. Abstract

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group, Castagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, Garcia F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Fabre-Colin C, Kjaer J, Grarup J, Costagliola D, Lodwick R, Ledergerber B, Phillips A.
Lancet Infect Dis. 2012 Feb;12(2):119-27. doi: 10.1016/S1473-3099(11)70248-1. Epub 2011 Oct 9. Abstract

Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia.
Bol SM, Booiman T, van Manen D, Bunnik EM, van Sighem AI, Sieberer M, Boeser-Nunnink B, de Wolf F, Schuitemaker H, Portegies P, Kootstra NA, van 't Wout AB.
PLoS One. 2012;7(2):e30990. doi: 10.1371/journal.pone.0030990. Epub 2012 Feb 7. Abstract

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group.
AIDS. 2012 Jan 28;26(3):315-23. doi: 10.1097/QAD.0b013e32834e8805. Abstract

Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.
Herbeck JT, Müller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, Gras L, Günthard HF, Jacobson LP, Mullins JI, Gottlieb GS.
AIDS. 2012 Jan 14;26(2):193-205. doi: 10.1097/QAD.0b013e32834db418. Abstract

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*
Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord.
HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17. Abstract

Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.
Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J; CASCADE Collaboration in EuroCoord.
Clin Infect Dis. 2012 Jan 1;54(1):111-8. doi: 10.1093/cid/cir814. Epub 2011 Nov 21. Abstract

 
 

Stichting HIV Monitoring

Stichting HIV Monitoring (SHM) levert een belangrijke en noodzakelijke bijdrage aan de zorg voor mensen met hiv in Nederland. Door middel van het verzamelen en bewerken van gecodeerde data van hiv-positieve personen uit het hele land draagt ons monitor-onderzoek structureel bij aan de kennis over hiv en stelt het behandelend artsen in staat om de zorg voor hun patiënten continu te verbeteren. Ons jaarlijkse Monitoring Report geeft waardevolle input voor het ontwikkelen van hiv-zorg en preventiebeleid in Nederland en binnen de Europese Unie.

Bezoekadres

Nicolaes Tulphuis
Tafelbergweg 51
1105 BD Amsterdam

Postadres

Academisch Medisch Centrum
Universiteit van Amsterdam
Meibergdreef 9 1105 AZ Amsterdam

© Stichting HIV Monitoring  | Disclaimer  | Colofon